FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - September 16, 2026 88 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... October 6, 2021 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... May 7, 2026 Load more HOT NEWS Qué debe saber sobre las pruebas de ADN en el hogar... Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly... ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed
